10.31.16
Fred M. Powell has been appointed senior vice president, chief financial officer, Antares Pharma, Inc. Mr. Powell has a diverse corporate background including more than 20 years of financial experience within the pharma and biopharma industries.
Most recently, Mr. Powell served as vice president and chief financial officer for Celator Pharmaceuticals, a publicly-held biopharmaceutical company developing a portfolio of cancer therapies, where he was responsible for the company’s accounting, corporate finance and financial planning functions and played an integral role in the sale of Celator to Jazz Pharmaceuticals for over $1.5 billion. Prior to Celator, Mr. Powell was the chief financial officer of OraPharma, and chief financial officer of BMP Sunstone Corp.
Robert F. Apple, president and chief executive officer Antares Pharma, said, “We are very pleased to have Fred join the executive leadership team at Antares Pharma, bringing with him over 25 years of extensive financial experience, including more than two decades of experience in the healthcare industry. I believe Fred’s arrival will have a positive impact on our future growth, given his track record of successful business transactions in the areas of license agreements, joint ventures and acquisitions.”
Most recently, Mr. Powell served as vice president and chief financial officer for Celator Pharmaceuticals, a publicly-held biopharmaceutical company developing a portfolio of cancer therapies, where he was responsible for the company’s accounting, corporate finance and financial planning functions and played an integral role in the sale of Celator to Jazz Pharmaceuticals for over $1.5 billion. Prior to Celator, Mr. Powell was the chief financial officer of OraPharma, and chief financial officer of BMP Sunstone Corp.
Robert F. Apple, president and chief executive officer Antares Pharma, said, “We are very pleased to have Fred join the executive leadership team at Antares Pharma, bringing with him over 25 years of extensive financial experience, including more than two decades of experience in the healthcare industry. I believe Fred’s arrival will have a positive impact on our future growth, given his track record of successful business transactions in the areas of license agreements, joint ventures and acquisitions.”